The Impact of Alloantibodies on Clinical VCA Outcomes and the Need for Immune Tolerance

• Published in: Transplantology (Basel, Switzerland) Vol. 5; no. 3; pp. 148 - 162
• Main Authors: Blades, Caitlin M., Navarro-Alvarez, Nalu, Huang, Christene A., Mathes, David W.
• Format: Journal Article
• Language: English
• Published: Birmingham MDPI AG 29.07.2024
• Subjects: alloantibody mediated rejection; Amputation; Animals; Antibodies; Bone marrow; donor-specific antibodies; Drug dosages; humoral immune response; immune tolerance; Immunotherapy; Lymphocytes; Toxicity; Transplants & implants; vascularized composite allotransplantation
• ISSN: 2673-3943; 2673-3943
• DOI: 10.3390/transplantology5030015

The functional outcomes and restoration of form after vascularized composite allotransplantation (VCA) have exceeded the results that could be achieved with current autologous surgical techniques. However, the longevity of VCA grafts has been limited due to the development of donor-specific antibodies (DSAs), and chronic rejection and graft failure occur despite long-term immunotherapy. Furthermore, despite widespread consensus that these non-life-saving transplants are beneficial for select patients, the application of VCA is limited by the need for lifelong immunosuppression. Therefore, attempts to achieve drug-free tolerance through safe and effective therapies are critical. This review highlights recent publications regarding alloantibody-mediated rejection (AMR) in various VCAs with a focus on the critical need for novel tolerance-inducing strategies. The development and implementation of effective methods of inducing tolerance, such as the use of anti-CD3 immunotoxins, could drastically improve VCA graft outcomes and recipient quality of life.